Request for Covid-19 Impact Assessment of this Report
The global fertility services market was estimated to be $16,761 million in 2016 and is expected to reach $30,964 million by 2023 growing with a CAGR of 9.3% during the market forecast period of 2017 to 2023. Fertility services consist of different procedures utilized to treat genetics & fertility issues and assists with conception. These fertility services include different assisted reproductive technology methods helping people with conception globally. The demand drivers of the global fertility services are rise in prevalence of delayed pregnancies and growth in infertility rates. The availability of latest medical technologies in IVF devices throughout the globe is expected to significantly fuel the market growth. The global fertility services market is anticipated to witness moderate growth during the market forecast period due to the rise in adoption of fertility services and rise in disposable income of the population. The health insurance portability and increase in advertising & marketing of medical institutes to promote artificial reproduction are expected to enhance the market growth significantly. However, cost involving fertility services and reimbursement issues related to fresh IVF cycles are expected to hamper the growth of the global fertility services market.
The global fertility service market is segmented based on procedure, services, end user and region. The global fertility service market based on procedure is classified into in-vitro fertilization (IVF), IVF with intracytoplasmic sperm injections (ICSI), IVF without ICSI, intrauterine insemination (IUI) and others. The global fertility services market by service is bifurcated into fresh non-donor, frozen non-donor, egg & embryo banking, fresh donor and frozen donor. The global fertility services market by end user is categorized into fertility clinics, hospitals, surgical centers and clinical research institutes. The global fertility services market by region is divided into North America, Europe, Asia-Pacific and LAMEA. The fertility clinics segment occupied the largest market share due to the availability and accessibility of different services related to IVF such as infertility treatment, IVF programs, Egg donation, Intracytoplasmic sperm injection, intracytoplasmic morphologically selected sperm injections and other. Asia-Pacific region possesses highest market potential for the growth of fertility services market due to increase in availability and accessibility of healthcare facilities and rise in healthcare & research expenditure. Asia-Pacific region is anticipated to experience rapid market growth due to economic development.
The key market players of the global fertility services market are Apollo Hospitals Enterprise Ltd, Care Fertility Group, Carolinas Fertility Institute, Genea Limited, The Johns Hopkins Health System Corp, Medicover Group, Monash IVF Group, OvaScience Inc, Progyny Inc, Xytex Cryo International, Irvine Scientific, INVO Bioscience, LifeGlobal Group, and IVFtech ApS.
Key Benefits for Stakeholders
Fertility Services Market Segments
By Procedure
CHAPTER 1 INTRODUCTION
1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS FOR STAKEHOLDERS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools & models
CHAPTER 2 EXECUTIVE SUMMARY
2.1. CXO PERSPECTIVE
CHAPTER 3 MARKET OVERVIEW
3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS
3.2.1. Top investment pockets
3.2.2. Top Winning Strategies
3.2.3. Top Winning Strategies, By Company, 2015-2017
3.3. PORTERS FIVE FORCE ANALYSIS
3.4. GOVERNMENT REGULATIONS
3.4.1. U.S.
3.4.1. Europe
3.5. INSURANCE REIMBURSEMENT SCENARIO
3.6. MARKET DYNAMICS
3.6.1. Drivers
3.6.1.1. Continuous decline in fertility rates
3.6.1.2. Delayed pregnancies in women
3.6.1.3. Technological advancements with respect to fertility treatment
3.6.2. Restraints
3.6.2.1. High treatment costs of ARTs in developed countries
3.6.2.2. Inadequate reimbursement policies
3.6.3. Opportunity
3.6.3.1. Rise in fertility tourism
CHAPTER 4 FERTILITY SERVICES MARKET, BY PROCEDURE
4.1. OVERVIEW
4.1.1. Market size and forecast
4.2. IVF WITH ICSI
4.2.1. Key market trends, growth factors, and opportunities
4.2.2. Market size and forecast
4.3. IUI
4.3.1. Key market trends, growth factors, and opportunities
4.3.2. Market size and forecast
4.4. IVF WITHOUT ICSI
4.4.1. Key market trends growth factors, and opportunities
4.4.2. Market size and forecast
4.5. SURROGACY
4.5.1. Key market trends, growth factors, and opportunities
4.5.2. Market size and forecast
4.6. OTHERS
4.6.1. Key market trends, growth factors, and opportunities
4.6.2. Market size and forecast
CHAPTER 5 FERTILITY SERVICES MARKET, BY SERVICE
5.1. OVERVIEW
5.1.1. Market size and forecast
5.2. FRESH NON-DONOR
5.2.1. Market size and forecast
5.3. FROZEN NON-DONOR
5.3.1. Market size and forecast
5.4. EGG AND EMBRYO BANKING
5.4.1. Market size and forecast
5.5. FRESH DONOR
5.5.1. Market size and forecast
5.6. FROZEN DONOR
5.6.1. Market size and forecast
CHAPTER 6 FERTILITY SERVICES MARKET, BY END USER
6.1. OVERVIEW
6.1.1. Market size and forecast
6.2. FERTILITY CLINICS
6.2.1. Market size and forecast
6.3. HOSPITALS
6.3.1. Market size and forecast
6.4. SURGICAL CENTERS
6.4.1. Market size and forecast
6.5. CLINICAL RESEARCH INSTITUTES
6.5.1. Market size and forecast
CHAPTER 7 FERTILITY SERVICES MARKET, BY REGION
7.1. OVERVIEW
7.1.1. Market size and forecast
7.2. NORTH AMERICA
7.2.1. Key market trends, growth factors, and opportunities
7.2.2. Market size and forecast, by country
7.2.3. Market size and forecast, by procedure
7.2.4. Market size and forecast, by service
7.2.5. Market size and forecast, by end user
7.2.5.1. U.S. market size and forecast
7.2.5.2. Canada size and forecast
7.2.5.3. Mexico market size and forecast
7.3. EUROPE
7.3.1. Key market trends, growth factors, and opportunities
7.3.2. Market size and forecast, by country
7.3.3. Market size and forecast, by procedure
7.3.4. Market size and forecast, by service
7.3.5. Market size and forecast, by end user
7.3.5.1. Germany market size and forecast
7.3.5.2. France market size and forecast
7.3.5.3. UK market size and forecast
7.3.5.4. Italy market size and forecast
7.3.5.5. Spain market size and forecast
7.3.5.6. Rest of Europe market size and forecast
7.4. ASIA-PACIFIC
7.4.1. Key market trends, growth factors, and opportunities
7.4.2. Market size and forecast, by country
7.4.3. Market size and forecast, by procedure
7.4.4. Market size and forecast, by service
7.4.5. Market size and forecast, by end user
7.4.5.1. Japan market size and forecast
7.4.5.2. India market size and forecast
7.4.5.3. China market size and forecast
7.4.5.4. Australia market size and forecast
7.4.5.5. South Korea market size and forecast
7.4.5.6. Taiwan market size and forecast
7.4.5.7. Rest of Asia-Pacific market size and forecast
7.5. LAMEA
7.5.1. Key market trends, growth factors, and opportunities
7.5.2. Market size and forecast, by country
7.5.3. Market size and forecast, by procedure
7.5.4. Market size and forecast, by service
7.5.5. Market size and forecast, by end user
7.5.5.1. Brazil market size and forecast
7.5.5.2. Turkey market size and forecast
7.5.5.3. Saudi Arabia market size and forecast
7.5.5.4. South Africa market size and forecast
7.5.5.5. Rest of LAMEA market size and forecast
CHAPTER 8 COMPANY PROFILES
8.1. APOLLO HOSPITALS ENTERPRISE LTD.
8.1.1. Company overview
8.1.2. Company snapshot
8.1.3. Operating business segments
8.1.4. Product portfolio
8.1.5. Business performance
8.1.6. Key strategic moves and developments
8.2. CARE FERTILITY GROUP
8.2.1. Company overview
8.2.2. Company snapshot
8.2.3. Product portfolio
8.2.4. Key strategic moves and developments
8.3. CAROLINAS FERTILITY INSTITUTE
8.3.1. Company overview
8.3.2. Company snapshot
8.3.3. Product portfolio
8.4. GENEA LIMITED
8.4.1. Company overview
8.4.2. Company snapshot
8.4.3. Operating business segments
8.4.4. Product portfolio
8.4.5. Key strategic moves and developments
8.5. THE JOHNS HOPKINS HEALTH SYSTEM CORP.
8.5.1. Company overview
8.5.2. Company snapshot
8.5.3. Operating business segments
8.5.4. Product portfolio
8.6. MEDICOVER GROUP
8.6.1. Company overview
8.6.2. Company snapshot
8.6.3. Operating business segments
8.6.4. Product portfolio
8.6.5. Business performance
8.7. MONASH IVF GROUP
8.7.1. Company overview
8.7.2. Company snapshot
8.7.3. Operating business segments
8.7.4. Product portfolio
8.7.5. Business performance
8.8. OVASCIENCE INC.
8.8.1. Company overview
8.8.2. Product portfolio
8.8.3. Business performance
8.8.4. Key strategic moves and developments
8.9. PROGYNY INC.
8.9.1. Company overview
8.9.2. Company snapshot
8.9.3. Product portfolio
8.9.4. Key strategic moves and developments
8.10. XYTEX CRYO INTERNATIONAL
8.10.1. Company overview
8.10.2. Company snapshot
8.10.3. Product portfolio
LIST OF TABLES
TABLE 1. KEY ART AND FERTILITY SERVICES LEGISLATION IN EUROPE: OVERVIEW
TABLE 2. INSURANCE COVERAGE FOR COUNTRIES
TABLE 3. FERTILITY SERVICES MARKET FOR IVF WITH ICSI, BY REGION, 2016-2023 ($MILLION)
TABLE 4. FERTILITY SERVICES MARKET FOR IUI, BY REGION, 2016-2023 ($MILLION)
TABLE 5. FERTILITY SERVICES MARKET FOR IVF WITHOUT ICSI, BY REGION, 2016-2023 ($MILLION)
TABLE 6. FERTILITY SERVICES MARKET FOR SURROGACY, BY REGION, 2016-2023 ($MILLION)
TABLE 7. FERTILITY SERVICES MARKET FOR OTHERS, BY REGION, 2016-2023 ($MILLION)
TABLE 8. GLOBAL FERTILITY SERVICES MARKET, BY SERVICE, 2016-2023 ($MILLION)
TABLE 9. FERTILITY SERVICES MARKET FOR FRESH NON-DONOR, BY REGION, 2016-2023 ($MILLION)
TABLE 10. FERTILITY SERVICES MARKET FOR FROZEN NON-DONOR, BY REGION, 2016-2023 ($MILLION)
TABLE 11. FERTILITY SERVICES MARKET FOR EGG AND EMBRYO BANKING, BY REGION, 2016-2023 ($MILLION)
TABLE 12. FERTILITY SERVICES MARKET FOR FRESH DONOR, BY REGION, 2016-2023 ($MILLION)
TABLE 13. FERTILITY SERVICES MARKET FOR FROZEN DONOR, BY REGION, 2016-2023 ($MILLION)
TABLE 14. GLOBAL FERTILITY SERVICES MARKET, BY END USER, 2016-2023 ($MILLION)
TABLE 15. FERTILITY SERVICES MARKET FOR IVF FERTILITY CLINICS, BY REGION, 2016-2023 ($MILLION)
TABLE 16. FERTILITY SERVICES MARKET FOR HOSPITALS, BY REGION, 2016-2023 ($MILLION)
TABLE 17. FERTILITY SERVICES MARKET FOR IVF SURGICAL CENTERS, BY REGION, 2016-2023 ($MILLION)
TABLE 18. FERTILITY SERVICES MARKET FOR CLINICAL RESEARCH INSTITUTES, BY REGION, 2016-2023 ($MILLION)
TABLE 19. FERTILITY SERVICES MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 20. NORTH AMERICA FERTILITY SERVICES MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 21. NORTH AMERICA FERTILITY SERVICES MARKET, BY PROCEDURE, 2016-2023 ($MILLION)
TABLE 22. NORTH AMERICA FERTILITY SERVICES MARKET, BY SERVICE, 2016-2023 ($MILLION)
TABLE 23. NORTH AMERICA FERTILITY SERVICES MARKET, BY END USER, 2016-2023 ($MILLION)
TABLE 24. EUROPE FERTILITY SERVICES MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 25. EUROPE FERTILITY SERVICES MARKET, BY PROCEDURE, 2016-2023 ($MILLION)
TABLE 26. EUROPE FERTILITY SERVICES MARKET, BY SERVICE, 2016-2023 ($MILLION)
TABLE 27. EUROPE FERTILITY SERVICES MARKET, BY END USER, 2016-2023 ($MILLION)
TABLE 28. ASIA-PACIFIC FERTILITY SERVICES MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 29. ASIA-PACIFIC FERTILITY SERVICES MARKET, BY PROCEDURE, 2016-2023 ($MILLION)
TABLE 30. ASIA-PACIFIC FERTILITY SERVICES MARKET, BY SERVICE, 2016-2023 ($MILLION)
TABLE 31. ASIA-PACIFIC FERTILITY SERVICES MARKET, BY END USER, 2016-2023 ($MILLION)
TABLE 32. LAMEA FERTILITY SERVICES MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 33. LAMEA FERTILITY SERVICES MARKET, BY PROCEDURE, 2016-2023 ($MILLION)
TABLE 34. LAMEA FERTILITY SERVICES MARKET, BY SERVICE, 2016-2023 ($MILLION)
TABLE 35. LAMEA FERTILITY SERVICES MARKET, BY END USER, 2016-2023 ($MILLION)
TABLE 36. APOLLO HOSPITALS: COMPANY SNAPSHOT
TABLE 37. APOLLO HOSPITALS: OPERATING SEGMENTS
TABLE 38. APOLLO HOSPITALS: PRODUCT PORTFOLIO
TABLE 39. CARE FERTILITY GROUP: COMPANY SNAPSHOT
TABLE 40. CARE FERTILITY GROUP: PRODUCT PORTFOLIO
TABLE 41. CAROLINAS FERTILITY INSTITUTE: COMPANY SNAPSHOT
TABLE 42. CAROLINAS FERTILITY INSTITUTE: PRODUCT PORTFOLIO
TABLE 43. GENEA LIMITED: COMPANY SNAPSHOT
TABLE 44. GENEA LIMITED: OPERATING SEGMENTS
TABLE 45. GENEA LIMITED: PRODUCT PORTFOLIO
TABLE 46. JHHS: COMPANY SNAPSHOT
TABLE 47. JHHS: OPERATING SEGMENTS
TABLE 48. JHHS: PRODUCT PORTFOLIO
TABLE 49. MEDICOVER: COMPANY SNAPSHOT
TABLE 50. MEDICOVER: OPERATING SEGMENTS
TABLE 51. MEDICOVER: PRODUCT PORTFOLIO
TABLE 52. MVF: COMPANY SNAPSHOT
TABLE 53. MVF: OPERATING SEGMENTS
TABLE 54. MVF: PRODUCT PORTFOLIO
TABLE 55. OVASCIENCE: COMPANY SNAPSHOT
TABLE 56. OVASCIENCE: PRODUCT PORTFOLIO
TABLE 57. PROGYNY: COMPANY SNAPSHOT
TABLE 58. PROGYNY: PRODUCT PORTFOLIO
TABLE 59. XYTEX: COMPANY SNAPSHOT
TABLE 60. XYTEX: PRODUCT PORTFOLIO
LIST OF FIGURES
FIGURE 1. FERTILITY SERVICES MARKET: MARKET SEGMENTATION
FIGURE 2. TOP INVESTMENT POCKETS
FIGURE 3. TOP WINNING STRATEGIES, BY YEAR, 2015-2017
FIGURE 4. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2015-2017 (%)
FIGURE 5. HIGH BARGAINING POWER OF BUYERS
FIGURE 6. MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 7. MODERATE THREAT OF SUBSTITUTION
FIGURE 8. MODERATE THREAT OF NEW ENTRANT
FIGURE 9. MODERATE COMPETITIVE RIVALRY
FIGURE 10. CDC (2017) DATA RELATED TO DELAYED PREGNANCY: KEY TAKEAWAYS
FIGURE 11. FERTILITY SERVICES MARKET: PROCEDURE SEGMENTATION
FIGURE 12. GLOBAL FERTILITY SERVICES MARKET, BY PROCEDURE, 2016-2023 ($MILLION)
FIGURE 13. ESTIMATED NUMBER OF BIRTHS PER WOMAN (GLOBAL FERTILITY RATE)
FIGURE 14. APOLLO HOSPITALS: NET SALES, 2015-2017 ($MILLION)
FIGURE 15. APOLLO HOSPITALS: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 16. MEDICOVER: NET SALES, 2015-2017 ($MILLION)
FIGURE 17. MEDICOVER: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 18. MEDICOVER: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 19. MVF: NET SALES, 2015-2017 ($MILLION)
FIGURE 20. MVF: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 21. OVASCIENCE: NET SALES, 2015-2017 ($MILLION)
The global digital pathology market was valued at $3,323 million in 2016, and is expected to reach $8,668 million by 2023, registering a CAGR of 14.8% during the forecast period. Digital pathology is defined as an image-based information setting enabled b...
The global regenerative medicine market was valued at $5,444 million in 2016, and is estimated to reach $39,325 million by 2023, registering a CAGR of 32.2% from 2017 to 2023. Regenerative medicines are used to repair, replace, and regenerate tissues & organs that are affected owin...
The medical robotics and computer-assisted surgery is a combination of equipment, accessories, software, and services that aid in performing different functions, such as robotic minimally invasive and non-invasive radiosurgeries, rehabilitation therapies, and hospital & pharmacy automation. Surgical robotics...